Merit Medical Systems, Inc. (MMSI)

Merit Medical Systems' stock price declined by 9.44% over six months. In Q3 CY2025, the company reported better-than-expected revenue of $384.2 million and non-GAAP EPS of $0.92, leading to raised full-year 2025 revenue and adjusted EPS guidance. Analyst sentiment has been generally positive, with Needham & Company LLC reaffirming a "Buy" rating and Piper Sandler reissuing an "Overweight" rating, though Zacks Research cut its rating to "Hold" in November. Insider selling has been noted, and CMS deferred a reimbursement decision for Merit's WRAPSODY CIE device, pushing potential incremental payments to 2027.

The medical devices and supplies industry, including Merit Medical Systems, benefits from relatively predictable revenue streams due to the recurring need for medical devices and growing global demand for advanced treatments. Significant seasonal fluctuations in demand are not a primary characteristic of this industry.

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical devices used in cardiovascular and endoscopy segments. The company's product portfolio includes vascular access, drainage, embolotherapy, interventional oncology devices, radiofrequency ablation systems, and hemostasis solutions. Key product categories also encompass peripheral intervention, cardiac intervention, custom procedural solutions, and OEM products. Merit Medical also offers specialized devices for gastroenterology and pulmonology, such as esophageal stents and balloon dilators, and products for lead management procedures. Notable products include the WRAPSODY® Cell-Impermeable Endoprosthesis and the SCOUT® Wire-Free Localization System.

Merit Medical Systems has a global presence with its headquarters in South Jordan, Utah, and manufacturing and distribution facilities in North America, Europe (Galway, Ireland), and Asia. Its products are sold in over 90 countries, supported by regional sales offices across North America, Europe, the Middle East, Africa, Asia, and Latin America.

Merit Medical Systems generally maintains a positive brand reputation, with a consensus rating of "Moderate Buy" from analysts. MarketBeat's MarketRank™ scored Merit Medical Systems higher than 79% of companies evaluated in the medical sector, and its responsibility reports have a high usefulness score. However, significant insider selling and the CMS deferral of the WRAPSODY CIE reimbursement decision could negatively impact investor confidence and product adoption.

Institutional investors heavily own Merit Medical Systems, holding approximately 85% to 99.66% of the company's stock. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, iShares Core S&P Small-Cap ETF, State Street Corp, Conestoga Capital Advisors, LLC, Fmr Llc, Maverick Capital Ltd, Geode Capital Management, Llc, and Wellington Management Group Llp. Insiders hold a smaller percentage, ranging from 2.36% to 3.70% of the stock, while public companies and individual investors account for the remaining shares.